HBSP (USA)
-
Bayer AG: Bidding to Win Merck's OTC Business
Esty, Benjamin C.; Baaij, Marc; Mulder, ArjenCase HBS-217021-EFinanceShortly after submitting their best and final offer to acquire Merck's Consumer Care Division, a collection of "over-the-counter" (OTC) products with sales totaling $2 billion, the Bayer M&A team was given a chance to revise their bid because another potential acquirer - likely Reckitt-Benckiser, a UK based company that had outbid them in a few prior acquisition auctions - had submitted a last-minute offer to Merck. Frank Rittgen (Head of M&A) an...Starting at €8.20
-
Catalys Pacific
Krieger, Joshua LevCase HBS-821035-EKnowledge and CommunicationIn 2019, BT Slingsby founds Catalys Pacific, the first biotech "venture creation" fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After examining hundreds of potential investment opportunities, his team must decide which deals to pursue first. How can Catalys Pacific establish a positive investment track record whi...Starting at €8.20
-
The "Wonder Drug" that Killed Babies
Krieger, Joshua Lev; Nicholas, Tom; Preble, MatthewCase HBS-818044-EEconomicsIn the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a certain stage of fetal development. As many as 10,000 children may have been affected. Just a handful of these children were born in the U.S., where safety concerns were raised by Dr. Frances Oldham Kelsey, the medical officer handling the thali...Starting at €8.20